Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Dec 8, 2014
Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders

Nov 19, 2014
Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
15.72
Change:
+ 0.81
Day High:
16.25
Day Low:
14.80
Volume:
1,222,600
4:00 PM ET on Dec 18, 2014

Shareholder Tools